



Bactiguard's BIP Foley Catheters approved for new patient groups

Bactiguard's BIP Foley Catheters in latex and silicone have been approved for new patient groups. The approval* includes patients who need suprapubic catheterization and long term usage.

"Bactiguard's growth strategy includes adding new devices and new applications to our product portfolio. The approval of our BIP Foley Catheters for suprapubic and long term usage is a significant step in this direction. It opens up a new market segment and will improve the quality of life for many patients who are dependent on catheters in their daily lives," says Johan Rugfelt, CEO.

Suprapubic catheterization, i.e. through the surgically created channel between the urinary bladder and the skin, is important for individuals with obstruction of normal urinary flow. It is also a common treatment used among patients suffering from injury of the spinal cord or neurological diseases like MS (Multiple Sclerosis). Suprapubic catheterization also poses less risk for catheter associated urinary tract infections.

The approval also includes catheterization for up to 12 weeks with a single unit, which gives physicians the opportunity to exchange catheters less frequently, provided that the catheter works well. This is a major advantage, since every catheter exchange is a risk for physical trauma to the urethra.

**The approval is valid in the EES and other countries that accept CE certification.*

BIP Foley Catheters

Increased patient safety with unique technology

Catheter associated urinary tract infections (CAUTI) account for a large proportion of healthcare associated infections (HAI). These infections can cause serious complications such as urosepsis, which leads to patient suffering as well as increased mortality and healthcare costs. In addition, many of these infections are treated with antibiotics, which increase the risk of emergence and spread of antibiotic-resistant bacteria. The BIP Foley Catheters are Bactiguard® coated indwelling urinary catheters made of latex or silicone. The Bactiguard® technology is clinically proven to reduce CAUTI and has been used successfully since 1995 for the prevention of HAI in the US and Japan, among other countries.

For more information, please contact:

Johan Rugfelt - CEO
johan.rugfelt@bactiguard.se
+46 708 724 739

Cecilia Edström - Director of Communications
cecilia.edstrom@bactiguard.se
+46 722 262 328

Bactiguard

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia.